These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 217694)

  • 1. Effect of polyenyl phosphatidyl choline on clofibrate-induced increase in LDL cholesterol.
    Schneider J; Müller R; Buberl W; Kaffarnik H; Schubotz R; Hausmann L; Mühlfellner G; Mühlfellner O
    Eur J Clin Pharmacol; 1979 Feb; 15(1):15-9. PubMed ID: 217694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of clofibrate on lipoprotein-lipids in patients with type IV hyperlipoproteinaemia (author's transl)].
    Weisweiler P; Schwandt P
    Klin Wochenschr; 1977 Aug; 55(16):791-4. PubMed ID: 198601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of a clofibrate-inositol nicotinate combination on lipids and lipoproteins in primary hyperlipoproteinemia of types IIa, IV and V].
    Hutt V; Wechsler JG; Klör HU; Ditschuneit H
    Arzneimittelforschung; 1983; 33(5):776-9. PubMed ID: 6683558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clofibrate-induced low density liporotein elevation. Therapeutic implications and treatment by colestipol resin.
    Rose HG; Haft GK; Juliano J
    Atherosclerosis; 1976; 23(3):413-27. PubMed ID: 178325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparison between combination therapy with clofibrate and beta-pyridylcarbinol and clofibrate monotherapy (author's transl].
    Mordasini R; Müller A; Klose G; Middelhoff G; Augustin J; Haase W; Greten H
    MMW Munch Med Wochenschr; 1978 Apr; 120(15):525-8. PubMed ID: 206826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of primary hyperlipoproteinemias. Comparison of N 041 with clofibrate].
    Gaertner U; Johannes KJ
    MMW Munch Med Wochenschr; 1976 Sep; 118(36):1127-30. PubMed ID: 184377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of clofibrate, nicotinic acid and diet on the properties of the plasma lipoproteins in a subject with type III hyperlipoproteinemia.
    Patsch JR; Yeshurun D; Jackson RL; Gotto AM
    Am J Med; 1977 Dec; 63(6):1001-9. PubMed ID: 204188
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of type III hyperlipoproteinemia with four different treatment regimens.
    Hoogwerf BJ; Bantle JP; Kuba K; Frantz ID; Hunninghake DB
    Atherosclerosis; 1984; 51(2-3):251-9. PubMed ID: 6588975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The concentration of high density lipoprotein in patients with type IV hyperlipoproteinemia and the effect of clofibrate.
    Brook JG; Lavy A; Aviram M; Zinder O
    Atherosclerosis; 1980 Aug; 36(4):461-9. PubMed ID: 7417365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic relationships among the plasma lipoproteins. Reciprocal changes in the concentrations of very low and low density lipoproteins in man.
    Wilson DE; Lees RS
    J Clin Invest; 1972 May; 51(5):1051-7. PubMed ID: 4341500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clofibrate and related compounds in hyperlipoproteinaemia. A review.
    Gustafson A
    Postgrad Med J; 1975; 51(8):suppl 66-71. PubMed ID: 215983
    [No Abstract]   [Full Text] [Related]  

  • 12. The treatment of hyperlipoproteinaemia with gemfibrozil compared with placebo and clofibrate.
    Nye ER; Sutherland WH; Temple Wa
    N Z Med J; 1980 Nov; 92(671):345-9. PubMed ID: 6935550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum-lipoprotein-cholesterol distribution in healthy men with high serum-cholesterol concentrations: Extrapolation to clofibrate trial.
    Carlson LA; Olsson AG
    Lancet; 1979 Apr; 1(8121):869-70. PubMed ID: 86108
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of vitamin E on serum cholesterol and triglycerides in hyperlipidemic patients treated with diet and clofibrate.
    Leonhardt ET
    Am J Clin Nutr; 1978 Jan; 31(1):100-5. PubMed ID: 202160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Type III hyperlipoproteinemia: rise in high-density lipoprotein levels in response to therapy.
    Falko JM; Witztum JL; Schonfeld G; Weidman SW; Kolar JB
    Am J Med; 1979 Feb; 66(2):303-10. PubMed ID: 218451
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of colestipol and clofibrate, singly and in combination, on plasma lipid and lipoproteins in type IIb hyperlipoproteinemia.
    Hunninghake DB; Bell C; Olson L
    Metabolism; 1981 Jun; 30(6):610-5. PubMed ID: 7231198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of probucol on serum lipoprotein levels in normal and dyslipoproteinemic mice.
    Tomikawa M; Nakayasu T; Tawara K; Abiko Y
    Atherosclerosis; 1981 Oct; 40(2):101-13. PubMed ID: 6946776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One-year trials with halofenate, clofibrate, and placebo.
    Dujovne CA; Azarnoff DL; Huffman DH; Pentikäinen P; Hurwitz A; Shoeman DW
    Clin Pharmacol Ther; 1976 Mar; 19(3):352-9. PubMed ID: 177242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clofibrate in type II hyperlipoproteinemia.
    Ditzel J; Bang HO
    Acta Med Scand; 1976; 200(1-2):55-58. PubMed ID: 183462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of colestipol and clofibrate on plasma lipid and lipoproteins in type IIa hyperlipoproteinemia.
    Hunninghake DB; Probstfield JL; Crow LO; Isaacson SO
    Metabolism; 1981 Jun; 30(6):605-9. PubMed ID: 7231197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.